NCT01477931

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

An Open-Label, 8-week Trial of Bupropion Hydrochloride Extended Release (Wellbutrin XL®) In Patients With Major Depressive Disorder (MDD) With Atypical Features.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Chi-Un Pae · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with MDD with atypical features.

Detailed description

Whether bupropion hydrochloride extended release (Wellbutrin XL®) improved atypical depressive symptoms has not been investigated. The investigators assumed that bupropion hydrochloride extended release (Wellbutrin XL®) will be effective and tolerable in the treatment of atypical depression in MDD patients.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	Bupropion extended release	300mg once a daily, PO, 8weeks

Timeline

• Start date: 2010-11-01
• Primary completion: 2011-07-01
• Completion: 2011-09-01
• First posted: 2011-11-23
• Last updated: 2011-11-23

Locations

6 sites across 1 country: South Korea